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Renal cysts, pain, and hematuria are common presentations
of autosomal dominant polycystic kidney disease (ADPKD) in
children. Renal function, however, is typically preserved in
these patients despite increased renal volume. Since
angiogenesis has been implicated in promotion of renal cyst
growth in ADPKD, we measured the serum level of various
angiogenic factors and early renal structural changes and
cardiovascular parameters in 71 patients with ADPKD, with
a mean age of 16 years. Renal structure and left ventricular
mass index were measured by magnetic resonance imaging
or by echocardiogram. Renal function was assessed by
creatinine clearance and urinary protein excretion. Serum
growth factor levels were measured by enzyme-linked
immunosorbent assay. Because of skewed distributions, the
various parameters are reported as log10. Serum log10
vascular endothelial growth factor was positively correlated
with renal and cardiac structure, but negatively with
creatinine clearance. Serum angiopoietin 1 levels significantly
correlated with structural change in both the kidney and the
heart and with urinary protein. Thus, the correlation between
angiogenic growth factors with both renal and cardiac
disease severity is compatible with a possible role for
angiogenesis in the early progression of disease in ADPKD.
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Autosomal dominant polycystic kidney disease (ADPKD)
affects between 1 in 400 and 1 in 1000 individuals in the
United States.1 Renal cysts are often evident on ultrasound
imaging in children who typically become symptomatic in
young adulthood.2–4 However, we have previously shown that
hypertensive (95th percentile for blood pressure) and border-
line hypertensive (75th–95th percentile for blood pressure)
children have a higher left ventricular mass index (LVMI)
than children with ADPKD and lower blood pressure.5
Moreover, hypertensive children with ADPKD have higher
renal volumes than children with lower blood pressure.6
Thus, careful clinical evaluation and monitoring of children
with ADPKD is critical.
It is apparent that vascular changes including expansion
and remodeling must occur in order to support the massive
growth of cysts in ADPKD patients. Evidence for angiogen-
esis in the form of development of a well-defined vascular
capsule around human renal cysts in ADPKD supports this
tenet.7,8 Moreover, the identification of angiogenic growth
factors including vascular endothelial growth factor (VEGF)
in the fluid from both human renal and hepatic cysts7–9 and
upregulated expression of angiopoietin (Ang)-1, Ang-2, and
their endothelial tyrosine kinase (Tie)-2 receptor in ADPKD
cholangiocytes supports a role of angiogenic growth factors
in mediating this process.10
VEGF is a central mediator of angiogenesis inducing
endothelial cell proliferation, sprouting, and promoting
vascular leakiness.11 The actions of the angiopoietins appear
to be both cell type-specific and dependent upon the
expression level of the respective growth factors. Ang-1
expressed by vascular smooth muscle cells and pericytes
activates the Tie-2 receptor resulting in blood vessel
stabilization.12 However, overexpression of Ang-1 has been
associated with increased sprouting and formation of larger
blood vessels in transgenic animal studies.13 In contrast, Ang-
2 causes destabilization of vessels, increased leakiness, and
enables function of other cytokines including VEGF.12 In
view of the potential opposing roles of Ang-1 and Ang-2, the
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Ang-1/Ang-2 ratio may also determine the biological
activity14–16 Several recent studies support an emerging role
for an imbalance of angiogenic growth factor levels in disease
processes including tumor growth, diabetes, chronic kidney
disease, and cardiovascular disease.12,17–20
As angiogenesis may be an important process for renal
cyst expansion, we hypothesized that the serum level of
angiogenic growth factors may be linked to measures of
disease progression in young patients with ADPKD. Children
and young adults with ADPKD present an ideal study
population, as renal cysts are present and actively growing.
But the disease is largely uncomplicated by features of
advanced renal damage including fibrosis, glomerulosclero-
sis, and inflammation.
RESULTS
Clinical and demographic characteristics of the study
patients
A total of 71 young patients with age range of 8–26 years, who
were enrolled in clinical studies at the University of Colorado
at Denver, and who underwent clinical and radiological
examination between 2000 and 2009 were included in the
study. The patient characteristics are presented in Table 1.
Serum VEGF levels were also assessed in 10 young patients
(5 male and 5 female) with type 1 diabetes mellitus (serum
hemoglobin A1c (%) 8.88±1.63) matched for age (15.7±2.3
years) and normal renal function (creatinine clearance
111±14 ml/min per 1.73 m2) to the young ADPKD patients.
Mean serum VEGF level was significantly lower in the young
diabetic patients compared with the ADPKD patients
(617±389 in diabetic patients compared with 2997±
5327 pg/ml in ADPKD patients, P¼ 0.0005).
Renal structure
Serum VEGF was strongly positively correlated with log10 total
renal and cyst volume (Table 2). The linear relationship
between log10 VEGF and total renal volume is illustrated in
Figure 1. Subjects with VEGF level 475th percentile also had
significantly greater log10 total renal and cyst volumes compared
with subjects with VEGF levelo50th percentile, after correction
for age and sex based on a P-value adjusted by Tukey–Kramer
correction for multiple comparisons21 (Figures 2, 3). Serum
Ang-1 was significantly positively correlated with log10 total
renal volume (P¼ 0.04) after correction for age, sex, and body
surface area (Table 2). There were no significant relationships
between renal structural parameters and Ang-2. However, the
ratio of Ang-1/Ang-2 was significantly and positively correlated
with log10 total renal volume, total cyst volume, and cyst count.
Renal function
There were significant correlations between Ang-1 and log10
urinary protein excretion (P¼ 0.009) after correction for
both age and sex (Table 3). The linear relationship is depicted
Table 1 | Clinical and demographic characteristics of study population
Parameter N Mean±s.d. Geometric mean and 95% CI
Age at evaluation (years) 71 16.3±4.0
Male (%) 29/71 (41%)
Height (cm) 71 165±14
Weight (kg) 71 66±23
Body surface area (BSA; m2) 71 1.71±0.34
Hypertension (%) 27/71 (38%)
Serum creatinine (mg/dl) 70 0.74±0.22 0.71 (0.66–0.76)
Ang-1 (ng/ml) 71 35.52±21.03 27.57 (22.56–33.69)
Ang-2 (pg/ml) 71 2.35±0.96 2.16 (1.96–2.39)
VEGF (pg/ml) 70 2997±5327 107.2 (42.78–268.6)
Urinary creatinine (mg/24 h) 68 1365.35±609.50 1250.24 (1129.1–1384.4)
Urinary protein (g/24 h) 67 0.20±0.28 0.14 (0.12–0.17)
Creatinine clearance (ml/min per 1.73m2) 70 130.24±29.40 125.02 (118.85–139.73)
Total renal volume (mm3) 61 653,795±573,871 506,0345 (423,634–604,464)
Total cyst volume (mm3) 61 430,273±534,914 254,174 (194,691–331,832)
Renal cyst count 61 74.5±42.6
LVMI (g/m2) 66 61.81±22.20 58.13 (53.29–63.41)
Abbreviations: Ang, angiopoietin; BSA, body surface area; CI, confidence interval; LVMI, left ventricular mass index; VEGF, vascular endothelial growth factor.
Table 2 | Relationship of VEGF, Ang-1, Ang-2, and ratio of
Ang-1/Ang-2 with renal structure
Dependent variable
Independent variable b s.e. P-value
Log10 total renal volume
Log10VEGF 0.0511 0.0183 0.0073
Ang-1 0.0029 0.0014 0.0448
Ang-2 0.00002 0.00003 0.5164
Ang-1/Ang-2 0.1611 0.0763 0.0393
Log10 total renal cyst volume
Log10VEGF 0.0862 0.0273 0.0026
Ang-1 0.004 0.0022 0.0680
Ang-2 0.00001 0.00005 0.9039
Ang-1/Ang-2 0.2616 0.1242 0.0397
Log10 total cyst number
Log10VEGF 0.0199 0.0192 0.3027
Ang-1 0.0025 0.0014 0.0789
Ang-2 0.00003 0.00003 0.3547
Ang-1/Ang-2 0.1923 0.0730 0.0109
Abbreviations: Ang, angiopoietin; VEGF, vascular endothelial growth factor.
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in Figure 4. There were no significant relationships between
serum VEGF or Ang-2 levels and urinary protein excretion.
The ratio Ang-1/Ang-2 was significantly correlated with log10
urinary protein excretion (Table 3).
In this group of young patients with ADPKD and renal
function largely preserved (creatinine clearance mean
130.24 ml/min per 1.73 m2), there was a significant negative
relationship between log10 VEGF and log10 creatinine
clearance (P¼ 0.02; Table 3). Subjects with VEGF level
475th percentile had significantly lower creatinine clearance
compared with those with VEGF levelo50th percentile, after
correction for multiple comparisons (Figure 5). No signifi-
cant relationships between Ang-1, Ang-2, Ang-1/Ang-2, and
creatinine clearance were found.
LVMI
Serum VEGF and Ang-1 were positively correlated with log10
LVMI after correction for age and sex (Pp0.0001 and
P¼ 0.04; Table 4). There was a linear relationship between
log10 VEGF and log10 LVMI as shown in Figure 6. Subjects
with VEGF level 475th percentile had significantly higher
LVMI compared with those with VEGF level between 50th
and 75th percentile and those with VEGF o50th percentile
after correction for age, sex, and correction for multiple
comparisons (Figure 7). Likewise, subjects with Ang-1 level
475th percentile had significantly higher LVMI compared
with those with Ang-1 level o50th percentile (P¼ 0.013)
after correction for age, sex, and correction for multiple
comparisons (data not shown). There were no significant
relationships between either Ang-2 level or the ratio Ang-1/
Ang-2 and LVMI.
Relationship between VEGF and Ang-1
Although the distribution of serum VEGF was highly skewed,
log10VEGF was significantly positively correlated with Ang-1
level (r¼ 0.37, P¼ 0.0019), but not with Ang-2 or with the
ratio Ang-1/Ang-2. Forward selection was used in multiple
linear regressions to determine independent effects of Ang-1,
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Figure 1 | Scatter plot of serum log10 vascular endothelial
growth factor (VEGF) and log10 total renal volume. The plot
depicts the uncorrected relationship between renal volume and
serum VEGF. VEGF pg/ml and renal volume mm3.
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Figure 2 | Total renal volume expressed by quartile of serum
vascular endothelial growth factor (VEGF) level. Renal volume
was adjusted for age, sex, and body surface area. VEGF range
o50th percentile o440 pg/ml; 50–75th percentile 224–2750
pg/ml; 475th percentile 2950–18,000 pg/ml. All P-values were
corrected for multiple comparisons by the Tukey–Kramer
correction.21
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Figure 3 |Total cyst volume expressed by quartile of serum
vascular endothelial growth factor (VEGF) level. Cyst volume
was adjusted for age and sex. VEGF range/quartile as presented in
legend for Figure 2. All P-values were corrected for multiple
comparisons by the Tukey–Kramer correction.21
Table 3 | Relationship of VEGF, Ang-1, Ang-2, and ratio of
Ang-1/Ang-2 with renal functional parameters including
urinary protein and creatinine clearance
Dependent variable
Independent variable b s.e. P-value
Log10 urinary protein excretion
Log10VEGF 0.0401 0.0209 0.0592
Ang-1 0.0042 0.0015 0.0093
Ang-2 0.00002 0.00004 0.5658
Ang-1/Ang-2 0.2050 0.0815 0.0145
Log10 creatinine clearance
Log10VEGF 0.0165 0.0070 0.0224
Ang-1 0.0010 0.0005 0.3020
Ang-2 0.00002 0.00001 0.1676
Ang-1/Ang-2 0.0102 0.0291 0.7283
Abbreviations: Ang, angiopoietin; VEGF, vascular endothelial growth factor.
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Ang-2, and VEGF on all dependent variables. Table 5 shows
that VEGF was selected over Ang-1 in the regression of total
renal volume, total cyst volume, LVMI, and creatinine
clearance. However, Ang-1 was selected over VEGF for uri-
nary protein excretion. The correlation of VEGF to Ang-1
and their individual relationships to ADPKD phenotypes
suggest a mediation effect of VEGF on Ang-1.
DISCUSSION
In this study we examined the relationship between the
angiogenic growth factors VEGF, Ang-1, and Ang-2 and renal
and cardiovascular disease progression in young patients with
ADPKD. Significant relationships were observed between
levels of VEGF, Ang-1, and Ang-1/Ang-2 and renal structural
disease, including total renal volume, total cyst volume, and
total cyst number (Table 2). These results are indicative of a
potential role for upregulated angiogenesis in early renal cyst
progression. Indeed, evidence of angiogenesis has previously
been demonstrated on the surface of renal cysts from patients
with ADPKD.7,8
Both human liver and renal ADPKD cyst fluids contain
VEGF, and a role for angiogenic growth factors in the growth
of liver cysts in ADPKD has previously been demonstrated.6,8
Expression of VEGF, VEGF receptor 1, Ang-1, and Tie-2 are
strongly upregulated in liver cholangiocytes from ADPKD
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Figure 4 | Scatter plot of serum angiopoietin (Ang)-1 and log10
urinary protein excretion. The plot depicts the uncorrected
relationship between 24 h urinary protein excretion and serum
Ang-1 level. Ang-1 ng/ml and urinary protein g/24 h.
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Figure 5 |Creatinine clearance expressed by quartile of serum
vascular endothelial growth factor (VEGF) level. Creatinine
clearance was corrected for height and weight and VEGF range/
quartile is presented in legend for Figure 1. All P-values were
corrected for multiple comparisons by the Tukey–Kramer
correction.21
Table 4 | Relationship of VEGF, Ang-1, Ang-2, and ratio of
Ang-1/Ang-2 with LVMI
Dependent variable
Independent variable b s.e. P-value
Log10VEGF 0.0409 0.0078 o0.0001
Ang-1 0.0014 0.0007 0.0407
Ang-2 0.00000 0.00002 0.8592
Ang-1/Ang-2 0.0397 0.0344 0.2531
Abbreviations: Ang, angiopoietin; LVMI, left ventricular mass index; VEGF, vascular
endothelial growth factor.
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Figure 6 | Scatter plot of serum log10 vascular endothelial
growth factor (VEGF) and log10 left ventricular mass index
(LVMI). The plot depicts the relationship between serum VEGF
and LVMI. VEGF pg/ml and LVMI g/m2.
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Figure 7 | Left ventricular mass index (LVMI) expressed by
quartile of serum vascular endothelial growth factor (VEGF)
level. LVMI is already adjusted for body surface area, but age and
sex were included as covariates. VEGF range/quartile as presented
in legend for Figure 1. All P-values were corrected for multiple
comparisons by the Tukey–Kramer correction.21
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patients,10 and inhibition of the VEGF receptor is known to
inhibit liver cyst growth in the pkd2(WS25/) mouse model
of ADPKD2, supporting a role for angiogenesis in liver cyst
growth.22 However, the current study, to the best of our
knowledge, is the first to support a relationship between
increased VEGF and angiopoietin with structural renal
disease progression in human ADPKD. In view of the
potential antagonistic effect of Ang-2 on Ang-1 activity,14–16
the Ang-1/Ang-2 ratio may impact biological activity. We
therefore also assessed the affect of the ratio on renal and
cardiac disease severity. Ang-1/Ang-2 was significantly related
to total cyst volume and notably the only measure
significantly, albeit weakly, related to total cyst number
(P¼ 0.01).
The serum level of VEGF and Ang-2 also appears to be
higher in young ADPKD patients compared with previously
reported values for healthy young subjects or those with
pathological conditions associated with elevated angiogenic
growth factors. In the current study, the mean serum VEGF
level was 2997 pg/ml compared with a literature reported
mean of 306 pg/ml in healthy children.23 In order to assess
whether the elevation in serum VEGF reflected impaired
renal clearance due to mild renal functional impairment or
loss of renal reserve, we compared serum VEGF levels in
young diabetic patients who were matched by age, sex, and
renal function with the ADPKD patients. Mean serum VEGF
level was significantly lower in the diabetic patients compared
with the level in the ADPKD patients. Similarly, Ang-2 level
in ADPKD was 2350 pg/ml compared with a literature rep-
orted control level of 68 (68–1330) pg/ml.14 Mysliwiec et al.24
reported a serum VEGF level of 312 (0–803) pg/ml in young
patients with diabetic retinopathy and a healthy control level
of 94 (13–328) pg/ml. This is also lower than the levels
observed in ADPKD patients in the current study. It should
also be noted that renal function was still within the normal
range in the young ADPKD subjects in the current study.
Serum angiogenic growth factor levels were also signifi-
cantly related to renal function. Ang-1 levels were signifi-
cantly correlated with urinary protein excretion (P¼ 0.009;
Table 3). Previous animal studies have demonstrated a strong
time-dependent expression of Ang-1 in glomeruli of a
diabetic rat model, and correlation with glomerular volume,
glomerular area, and urinary protein.25 Serum VEGF level
was correlated with creatinine clearance (P¼ 0.022; Table 3).
This result indicates that serum VEGF may indicate very
early renal changes as kidney function is essentially preserved
in young patients with ADPKD. The mean creatinine
clearance in the current study was 130.24±29.4 ml/min per
1.73 m2 (Table 1).
Significant positive correlations between LVMI and Ang-1
and VEGF were also demonstrated in the current study. In
particular, log10 transformed VEGF level was strongly related
to LVMI after correction for age and sex (Po0.0001; Table 4,
Figure 7). This is of particular relevance as patients with
ADPKD are at an increased risk for left ventricular
hypertrophy.26 Moreover, higher serum VEGF level in young
ADPKD patients in the current study was associated
with elevated LVMI even in the absence of overt hyperten-
sion. We have previously shown increased LVMI in children
with ADPKD who are hypertensive or who have borderline
hypertension (blood pressure between 75th and 95th
percentile for age, height, and sex).5 Identification of children
at risk for cardiovascular complications is important because
cardiac magnetic resonance imaging and/or echocardiogra-
phy are not routinely performed on young patients with
ADPKD. However, future studies to investigate the role of
angiogenic growth factors in the etiology of cardiac damage
in ADPKD will be necessary.
Previous studies have demonstrated increased plasma and
platelet levels of Ang-1 and VEGF in hypertension that
decreased with treatment.19 In the current study, 26 subjects
were hypertensive (blood pressure X95th percentile for age,
height, and sex) and 45 were normotensive. However, there
Table 5 | Stepwise linear regression models using forward
selection to determine independent effects of Ang-1, Ang-2,
and VEGF
Dependent variable
Independent variable Partial R2 Model R2 P-value
Log10 total renal volume
Age 0.2863 0.2863 o0.0001
Sex 0.1379 0.4242 0.0006
Log10VEGF 0.0723 0.4965 0.0068
Ang-1 0.0163 0.5128 0.1846
Ang-2 0.0065 0.5193 0.4013
Log10 total renal cyst volume
Age 0.2722 0.2722 o0.0001
Sex (male) 0.1314 0.4036 0.0010
Log10VEGF 0.0929 0.4966 0.0026
Ang-1 0.0070 0.5036 0.3908
Log10 total cyst number
Sex 0.0941 0.0941 0.0181
Age 0.0698 0.1638 0.0349
Ang-1 0.0490 0.2128 0.0697
Log10VEGF 0.0539 0.2668 0.0513
Ang-2 0.0150 0.2818 0.2973
Log10 LVMI
Log10VEGF 0.3965 0.3965 o0.0001
Age 0.1446 0.5412 o0.0001
Sex 0.0764 0.6175 0.0009
Log10 urinary protein excretion
Sex 0.1943 0.1943 0.0002
Ang-1 0.0989 0.2932 0.0042
Log10VEGF 0.0143 0.3075 0.2616
Ang-2 0.0062 0.3137 0.4607
Log10 creatinine clearance
Log10VEGF 0.0801 0.0801 0.0224
Ang-2 0.0308 0.1108 0.1480
Abbreviations: Ang, angiopoietin; VEGF, vascular endothelial growth factor.
Note that all models included log10 VEGF, Ang-1, Ang-2, and appropriate covariates.
Ratio of Ang-1/Ang-2 was not included owing to significant collinearity with Ang-1
and Ang-2. Entries represent a summary of forward selection with variables that
remained in the model and the order of selection. Po0.15 was required to remain in
the model.
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was no effect of Ang-1 (odds ratio¼ 0.993 (0.969–1.018),
P¼ 0.59) and VEGF (odds ratio¼ 0.765 (0.548–1.068),
P¼ 0.1159) on the presence of hypertension. Moreover, it
has previously been shown that hypertensive patients with
target organ damage (stroke, myocardial infarction, angina,
left ventricular hypertrophy, and mild renal failure) had
higher levels of VEGF and Ang-1.20 This report agrees with
the findings of our current study and indicates that both
Ang-1 and VEGF may have potential roles in the early stages
of renal and cardiac damage in ADPKD.
In the current study, a relationship between VEGF level
and Ang-1 was demonstrated. Furthermore, forward selec-
tion in multiple linear regression used to assess independent
effects of Ang-1 and VEGF on all dependent variables suggest
a mediation effect of VEGF on Ang-1 (Table 5). Stimulation
of Ang-1 by VEGF has previously been demonstrated in
bovine retinal pericytes.27 In addition, a recent study
demonstrated that VEGF activates Tie-2 via proteolytic
cleavage of the Tie-1 tyrosine kinase resulting in transpho-
sphorylation and activation of Tie-2.28 This suggests a
synergistic action of the angiopoietin and VEGF growth
factors. However, while VEGF appeared to have a stronger
relationship to renal structural parameters and LVMI,
notably each growth factor had a unique relationship
between specific renal functional parameters as evidenced
by the relationship between VEGF and creatinine clearance
and Ang-1 with urinary protein excretion.
Activation of the renin–angiotensin system occurs early
in ADPKD29–32 and may in part explain the upregulated
expression of both VEGF and angiopoietins. In rats, increased
renal expression of VEGF, Ang-1, and Ang-2 following infusion
of angiotensin has previously been demonstrated.33,34 Further-
more, Ang-2 has been shown to stimulate division of human
endothelial cells in culture and to upregulate expression of
VEGF.35 These effects were blocked by candesartan implicating
involvement of the angiotensin-1 receptor.
In conclusion, VEGF level increases with expanding
kidney volume and rise in LVMI, possibly reflecting a role
of this growth factor in early renal and cardiac disease
progression in ADPKD. Future animal and cell studies that
focus on angiogenesis in ADPKD models will be required to
unravel the involved molecular mechanisms, but may provide
potential new therapeutic targets for ADPKD.
METHODS
Patient description and clinical evaluation
All patients gave informed consent to a protocol that was
approved by the Colorado Multiple Institute Review Board.
Patients were recruited from those participating in ongoing
clinical studies of ADPKD at the University of Colorado
Denver between 1990 and 2009. ADPKD diagnosis was based
on radiographic imaging and Ravine’s criteria;36 all patients
included in this study had a positive family history of
ADPKD. All patients were studied during a 2-day in-patient
visit at the Pediatric Clinical Translational Research Center at
the Children’s Hospital in Denver Colorado, as described
previously.5 Serum and urine creatinine, height, and weight
were used to calculate creatinine clearance for all subjects.
Blood was drawn for serum chemistries and growth factor
assay. Two 24 h urines were collected for urinary protein
excretion and the value reported is the mean for both 24 h
urines. Urinary protein was determined in the hospital core
laboratory by the pyrogallol red method. Left ventricular
mass was determined by standard two-dimensional and
Doppler echocardiogram as previously described5 or by
cardiac magnetic resonance imaging on a 1.5 T Siemens
system (Siemens, Malvern, PA, USA). Cardiac-gated breath-
hold two dimensional true-Fast Imaging with Steady state
Precession (Fast Imaging Employing Steady-state Acquisi-
tion) short-axis cine images were obtained to cover the left
ventricle atrioventricular ring to apex (10 mm slice thickness,
no gap, field of view 250–320 mm; 10–15 breath holds to
cover the whole ventricle). The imaging protocol consisted of
localizers in three orthogonal planes (axial, coronal, and
sagital). After the data were acquired, a Leonardo (Siemens
Medical System) workstation was used to manually contour
endocardial and epicardial contours of the left ventricle in
end-diastole and end-systole, and left ventricular mass was
calculated. Left ventricular mass was corrected by body
surface area and reported as LVMI in g/m2.
Angiopoietin and VEGF assay
Patient sera were stored at –80 1C before assay and all samples
were assayed in duplicate. Ang-1 and VEGF were assayed by
enzyme-linked immunosorbent assay using kits from Ray-
biotech (Norcross, GA, USA). The intra- and inter-assay
coefficient of variability of the Ang-1 assay was o10% and
o12%, respectively, and lower limit of detection 30 pg/ml.
The VEGF intra- and inter-assay coefficient of variability was
o10 and o12%, respectively, with lower limit of detec-
tion 20 pg/ml. Serum Ang-2 was assayed by Quantikine
enzyme-linked immunosorbent assay from R&D Systems
(Minneapolis, MN, USA). The intra- and inter-assay
reproducibility was 7 and 10.4%, respectively, with lower
limit of detection, 21.3 pg/ml.
Statistical analysis
All variables were checked for the distributional assumption
of normality. Owing to the highly skewed distributions of all
outcome variables, log10 transformations were applied and
the transformed variables were used in all analyses. Log10
transformations were also applied to VEGF and the ratio of
Ang-1/Ang-2. All statistical analyses were performed using
SAS version 9.2 (SAS Institute, Cary, NC, USA). Descriptive
statistics are presented as mean, s.d., and 95% confidence
interval or geometric mean and 95% confidence interval.
Univariate linear regression was used to test the relationship
of VEGF, Ang-1, Ang-2, and the ratio of Ang-1/Ang-2 on
ADPKD phenotypes including total renal volume, total cyst
number, total cyst volume, creatinine clearance, LVMI, and
urinary protein excretion. Stepwise linear regression was used
with the forward selection method to determine independent
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effects of Ang-1, Ang-2, and VEGF on all dependent
variables. No correction for multiple end points was applied;
however, the primary hypothesis was that Ang-1 would
be related to kidney volume measures. In linear regression,
renal volume was adjusted for age, sex, and body surface area,
renal cyst volume was adjusted for age and sex. Creatinine
clearance was corrected for bovine serum albumin, and
proteinuria was corrected for age and sex. LVMI was already
adjusted for body surface area, but age and sex were included
as covariates. Logistic regression was used to test the
relationship of VEGF, Ang-1, Ang-2, and ratio Ang-1/Ang-2
with hypertension. In analysis of total renal volume, total cyst
volume, creatinine clearance, and LVMI by quartile of VEGF;
all P-values were corrected for multiple comparisons by the
Tukey–Kramer correction.21
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